. 2014 Dec;66(Suppl 3):S1–S51. doi: 10.1016/j.ihj.2014.12.001

Table 10.

Cardiovascular benefits of statins in placebo-controlled primary prevention clinical trials.

Trial	Population	Statin dosage	LDL-C reduction	Effective AGAINST CHD	Effective AGAINST stroke
AFCAPS/TEXCAPS²¹²	5608 men aged 45–73 and 997 women aged 55–73 y with lipid entry criteria (low HDL-C required)	Lovastatin 20 mg and 40 mg/day	25%	Yes	NR
WOSCOPS²¹³	High-risk men aged 45–64 y without prior MI, followed up for 4.9 y	Pravastatin 40 mg/day	26%	Yes	No
ASCOT-LLA²¹⁴	10,305 hypertensive patients aged 40–79 y with atleast three other CV risk factors, followed up for 3.3 y before study was halted by the data safety and monitoring board	Atorvastatin 10 mg/day	29%	Yes	Yes
ALLHAT-LLA²¹⁵	10,355 subjects aged ≥ 25 y who met lipid criteria, monitored for up to 8 y	Pravastatin 40 mg/day	16.7% (related to drop-insin placebo group and drop-outs in treatment groups)	No; because of less marked LDL-C difference between the two groups due to high crossover and dropout rates	No
JUPITER¹¹⁸	17,802 apprentlyhealthy men and women with LDL-C <130 mg/dl and hs-CRP 2.0 or higher	Rosuvastatin 20 mg/day	50%	Yes	Yes
CARDS²¹⁶	2838 men and women with type 2 diabetes and ≥1 other risk factor	Atorvastatin 10 mg/day	40%	Yes	Yes

AFCPS/TEXCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study, ALLHAT-LLA-Antihypertensive and Lipid Lowering to Prevent Heart Attacks Trial, ASCOT-LLA – Anglo-Scandinavian Cardiac Outcomes Trial Lipid Lowering Arm, CARDS – Collaborative Atorvastatin Diabetes study; CHD-coronary heart disease, JUPITER – Justification for the Use of Statins in Prevention- An Intervention Trial Evaluating Rosuvastatin; LDL-C low density lipoprotein cholesterol; MI-myocardial infarction; NR-not reported, WOSCOPS-West of Scotland Coronary Prevention Study.